The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Factors influencing the choice of intensive therapy in AML: age, performance status & genetics
Alex Bataller, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, highlights key factors that can help determine how to choose between intensive chemotherapy versus lower-intensity approaches in patients with acute myeloid leukemia (AML), including age, performance status, and genetics. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
